Trial Profile
Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 20 mg granules for oral suspension rivaroxaban versus 20 mg tablets rivaroxaban under fed condition in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Rivaroxaban
- Indications Acute coronary syndromes; Cardiovascular disorders; Coronary thrombosis; Deep vein thrombosis; Embolism; Peripheral arterial disorders; Pulmonary embolism; Stroke; Thromboembolism; Thrombosis; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Bayer
- 10 Nov 2017 Status changed from recruiting to completed.
- 22 Jun 2017 New trial record